Skip to Main Content

Contribute Try STAT+ Today

Merck

Most Read

red SARS-CoV-2

Health By Andrew Joseph and Helen Branswell

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants

Martin Shkreli website

Pharmalot By Ed Silverman

Martin Shkreli’s former company pays $40 million for blocking competition for a life-saving drug

pill dollar sign list price

Pharmalot By Ed Silverman

Centene agrees to pay $28 million to resolve another state probe into its pharmacy benefits business

Nasdaq

Health Tech By Casey Ross and Maddie Bender

Pear makes its stock market debut & telehealth players lock arms

Priscilla Chan

Exclusive By Katie Palmer

‘A multi-decade journey’: Chan Zuckerberg Initiative invests another $3.4 billion to advance scientific tools

Pharmalot By Ed Silverman

Pharmalittle: Glaxo and Vir antibody remains effective against Omicron; Biden talks up drug-pricing reform

Health By Angus Chen and Olivia Goldhill

STAT+ Conversation: The ‘Shroom Boom’

In the Lab By Angus Chen

Is cancer biology research reproducible? After a decade of work, the answer still isn’t clear

All Coverage

Insulin

Business By Rebecca Robbins

The insulin market is heading for a shakeup. But patients may not benefit

Pharmalot By Ed Silverman

European regulators appeal rulings that prevent release of drug data

advertisement

Emma Walmsley

Pharmalot By Ed Silverman

Glaxo’s new CEO will be first female head of global drug company

Pharmalot By Ed Silverman

Parents remain leery of schools that require HPV vaccination

Pharmalot By Ed Silverman

A key trial for a Bristol-Myers cancer drug fails in a ‘major surprise’

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Biogen is the latest pharma takeover target

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant losing a crucial revenue tool

Pharmalot By Ed Silverman

Merck Ebola vaccine wins speedier reviews by regulators

Pharmalot By Ed Silverman

Merck to cut 360 R&D jobs, close one facility, and expand elsewhere

Moderna

Business By Robert Weisman — Boston Globe

Moderna gets $200m in expanded Merck deal

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: FDA staff questions effectiveness of Merck antibiotic

Pharmalot By Ed Silverman

Gilead won’t have to pay $200 million in patent case because Merck lawyer lied

Hires -- up and down the ladder

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: FDA approves Roche bladder cancer drug

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Investors tell pharma to ‘take control’ of the pricing debate

Cash back

The Pharmalot View By Ed Silverman

Big drug maker presses for money-back guarantee that its science will work

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: China probing drug and device makers for antitrust violations

Merck

Pharmalot By Ed Silverman

Merck fights with New Zealand over coverage of its Keytruda cancer drug

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: ‘Valeant was a sewer,’ says Berkshire’s Munger

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant plans to overhaul its board

Gardasil dose

Pharmalot By Ed Silverman

Switching to newest HPV vaccine can save billions in health care costs, study says

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Gilead ordered to pay $200m to Merck in patent row

Pharmalot By Ed Silverman

Merck wins high-stakes battle with Gilead over hep C patents

Hires -- up and down the ladder

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Gilead and Merck battle over hepatitis C patents